CRISPR THERAPEUTICS AG — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-149.2% -$164M
$-54M
Free Cash Flow↓-103.5% -$263K
$-517K
Investing Cash Flow↓-64.8% -$69M
$37M
Financing Cash Flow↑+589.8% +$100M
$116M
Capex↑+103.5% +$263K
$517K
Stock Buybacks
—
Stock-Based Comp↓-17.6% -$4M
$18M
D&A↑+16.9% +$819K
$6M
SBC Allocated Expense↓-17.6% -$4M
$18M